Impact of risk adjustment for drug-resistant types on tuberculosis patients' outcomes under China's innovative payment methods: a quasi-experimental study design.

ABSTRACT:

Background

Treating drug-resistant tuberculosis (DR-TB) is clinically complex and economically burdensome compared to drug-susceptible tuberculosis (DS-TB). China's diagnosis-intervention packet payment system initially omitted risk adjustment for drug resistance. In 2022, a diagnosis-intervention packet (DIP)-pilot city implemented such adjustment, establishing distinct reimbursement standards for DR-TB and DS-TB. This study aimed to assess the impact of this DR-type risk adjustment on medical expenditures, treatment efficiency, and care quality for TB patients.

Methods

A quasi-experimental difference-in-differences design was employed, involving 8465 TB patients from June 2021 to December 2023. Linear regression was performed with time and treat fixed effects and the inter

SUBMITTER: Zhao M 

PROVIDER: S-EPMC12906684 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature